Incyte (INCY) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $113.07, -0.18% vs the prior close of $113.27.
- Volume 1.58M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
INCY ends flat (-0.2%) to $113.07. Closed at $113.07, -0.18% vs the prior close of $113.27. Day range $112.02–$114.56, opened at $113.96.
INCY daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — INCY ends flat (-0.2%) to $113.07
- Closed at $113.07, -0.18% vs the prior close of $113.27. Day range $112.02–$114.56, opened at $113.96.
- Volume was 1.58M shares, 1.0x its 50-day average of 1.52M.
- Price is -7.2% vs its 50-day average ($121.83) and +5.2% vs its 200-day average ($107.50).
- 52-week range $84.02–$132.60; today's close sits at 60% of that range, 14.7% below the 52-week high.
Oct 15, 2026 — INCY rises 1.5% to $113.27
- Closed at $113.27, +1.52% vs the prior close of $111.57. Day range $112.60–$116.03, opened at $112.71.
- Volume was 1.94M shares, 1.3x its 50-day average of 1.52M.
- Price is -7.1% vs its 50-day average ($121.94) and +5.4% vs its 200-day average ($107.43).
- 52-week range $84.02–$132.60; today's close sits at 60% of that range, 14.6% below the 52-week high.
Oct 14, 2026 — INCY rises 2.7% to $111.57
- Closed at $111.57, +2.72% vs the prior close of $108.62. Day range $107.83–$112.06, opened at $108.61.
- Volume was 1.87M shares, 1.2x its 50-day average of 1.52M.
- Price is -8.6% vs its 50-day average ($122.07) and +3.9% vs its 200-day average ($107.36).
- 52-week range $83.46–$132.60; today's close sits at 57% of that range, 15.9% below the 52-week high.
Oct 13, 2026 — INCY dips 2.5% to $108.62, a 3-month low
- Closed at $108.62, -2.46% vs the prior close of $111.36. Day range $107.78–$111.68, opened at $111.29.
- Volume was 2.59M shares, 1.7x its 50-day average of 1.50M.
- Price is -11.2% vs its 50-day average ($122.25) and +1.2% vs its 200-day average ($107.30).
- 52-week range $82.82–$132.60; today's close sits at 52% of that range, 18.1% below the 52-week high.
Oct 12, 2026 — INCY dips 1.3% to $111.36, a 3-month low
- Closed at $111.36, -1.27% vs the prior close of $112.79. Day range $111.26–$114.05, opened at $114.05.
- Volume was 1.48M shares, 1.0x its 50-day average of 1.51M.
- Price is -9.1% vs its 50-day average ($122.45) and +3.8% vs its 200-day average ($107.26).
- 52-week range $82.82–$132.60; today's close sits at 57% of that range, 16.0% below the 52-week high.
Oct 9, 2026 — INCY ends flat (+0.0%) to $112.79
- Closed at $112.79, +0.04% vs the prior close of $112.75. Day range $111.81–$113.87, opened at $112.35.
- Volume was 1.12M shares, 0.7x its 50-day average of 1.54M.
- Price is -8.0% vs its 50-day average ($122.61) and +5.2% vs its 200-day average ($107.21).
- 52-week range $82.82–$132.60; today's close sits at 60% of that range, 14.9% below the 52-week high.
Oct 8, 2026 — INCY dips 0.6% to $112.75
- Closed at $112.75, -0.61% vs the prior close of $113.44. Day range $110.08–$113.75, opened at $112.89.
- Volume was 1.93M shares, 1.2x its 50-day average of 1.56M.
- Price is -8.2% vs its 50-day average ($122.81) and +5.2% vs its 200-day average ($107.15).
- 52-week range $82.82–$132.60; today's close sits at 60% of that range, 15.0% below the 52-week high.
Oct 7, 2026 — INCY rises 0.6% to $113.44
- Closed at $113.44, +0.63% vs the prior close of $112.73. Day range $112.46–$115.49, opened at $112.82.
- Volume was 1.27M shares, 0.8x its 50-day average of 1.65M.
- Price is -7.8% vs its 50-day average ($123.10) and +5.9% vs its 200-day average ($107.10).
- 52-week range $82.82–$132.60; today's close sits at 62% of that range, 14.4% below the 52-week high.
Oct 6, 2026 — INCY dips 1.2% to $112.73, a 3-month low, 6 down days in a row
- Closed at $112.73, -1.23% vs the prior close of $114.13. Day range $111.67–$114.97, opened at $114.13.
- Volume was 2.46M shares, 1.5x its 50-day average of 1.65M.
- Price is -8.7% vs its 50-day average ($123.43) and +5.3% vs its 200-day average ($107.02).
- 52-week range $82.82–$132.60; today's close sits at 60% of that range, 15.0% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — INCY dips 1.0% to $114.13, a 3-month low, 5 down days in a row
- Closed at $114.13, -1.01% vs the prior close of $115.30. Day range $112.83–$115.67, opened at $115.15.
- Volume was 1.95M shares, 1.2x its 50-day average of 1.64M.
- Price is -7.6% vs its 50-day average ($123.55) and +6.7% vs its 200-day average ($106.94).
- 52-week range $82.82–$132.60; today's close sits at 63% of that range, 13.9% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — INCY dips 1.6% to $115.30, a 1-month low, 4 down days in a row
- Closed at $115.30, -1.57% vs the prior close of $117.14. Day range $114.57–$117.19, opened at $116.76.
- Volume was 2.17M shares, 1.3x its 50-day average of 1.61M.
- Price is -6.7% vs its 50-day average ($123.63) and +7.9% vs its 200-day average ($106.86).
- 52-week range $82.82–$132.60; today's close sits at 65% of that range, 13.0% below the 52-week high.
- That makes 4 straight losses.
INCY latest news & SEC filings
Every SEC filing by or about INCY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Heeson Lee had withheld for taxes 463 shares at $117.14 (≈$54.24K) on Oct 1, 2026; now holds 37,578
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Baker Bros. Advisors Lp & 667, L.P. & Baker Bros. Advisors (Gp) Llc & Baker Brothers Life Sciences Lp & Baker Felix & Baker Julian received an award of 322 shares on Sep 30, 2026; now holds 2,835,403
- Baker Bros. Advisors Lp & 667, L.P. & Baker Bros. Advisors (Gp) Llc & Baker Brothers Life Sciences Lp & Baker Felix & Baker Julian received an award of 322 shares on Sep 30, 2026; now holds 28,206,082
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Clancy Paul J received an award of 203 shares at $121.35 (≈$24.63K) on Sep 30, 2026; now holds 25,838
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Harrigan Edmund received an award of 206 shares at $121.35 (≈$25.00K) on Sep 30, 2026; now holds 23,225
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gardner David H had withheld for taxes 920 shares at $126.93 (≈$116.78K) on Sep 22, 2026; now holds 15,904
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cagnoni Pablo J converted options/RSUs into 2,957 shares at $61.76 (≈$182.62K) on Sep 15, 2026; now holds 186,157
- Cagnoni Pablo J converted options/RSUs into 4,551 shares at $61.18 (≈$278.43K) on Sep 15, 2026; now holds 190,708
- Cagnoni Pablo J converted options/RSUs into 6,477 shares at $64.25 (≈$416.15K) on Sep 15, 2026; now holds 197,185
- Cagnoni Pablo J converted options/RSUs into 9,233 shares at $71.93 (≈$664.13K) on Sep 15, 2026; now holds 206,418
- Cagnoni Pablo J sold 9,233 shares at $120.50 (≈$1.11M) on Sep 15, 2026; now holds 197,185
- Cagnoni Pablo J sold 13,985 shares at $120.49 (≈$1.69M) on Sep 15, 2026; now holds 183,200
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 31, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 28, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Key figures from this report aren't in the SEC's structured data yet (usually appears within a day or two).
Jul 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jun 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade INCY
- Last results release: Jul 28, 2026 (8-K Item 2.02). Previous ones: Apr 28, 2026, Feb 10, 2026, Oct 28, 2025. Based on that rhythm, the next report is likely around Oct 27, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.25% (largest 3.5%).
- Liquidity: about 1.73M shares (≈$195.37M) trade per day on average.
- 52-week position: $113.07 vs a range of $84.02–$132.60 (60% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Pablo J Cagnoni sold 9,233 shares on Sep 15, 2026.
- Latest filings: 8-K Aug 31, 2026; 10-Q Jul 28, 2026; 8-K Jul 28, 2026.
- Share count: 199.78M shares outstanding (Apr 21, 2026), +3.2% vs a year earlier.
- Listing: Nasdaq · industry: Services-Commercial Physical & Biological Research.
INCY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 113.96 | 114.56 | 112.02 | 113.07 | 1.58M |
| Oct 15, 2026 | 112.71 | 116.03 | 112.60 | 113.27 | 1.94M |
| Oct 14, 2026 | 108.61 | 112.06 | 107.83 | 111.57 | 1.87M |
| Oct 13, 2026 | 111.29 | 111.68 | 107.78 | 108.62 | 2.59M |
| Oct 12, 2026 | 114.05 | 114.05 | 111.26 | 111.36 | 1.48M |
| Oct 9, 2026 | 112.35 | 113.87 | 111.81 | 112.79 | 1.12M |
| Oct 8, 2026 | 112.89 | 113.75 | 110.08 | 112.75 | 1.93M |
| Oct 7, 2026 | 112.82 | 115.49 | 112.46 | 113.44 | 1.27M |
| Oct 6, 2026 | 114.13 | 114.97 | 111.67 | 112.73 | 2.46M |
| Oct 5, 2026 | 115.15 | 115.67 | 112.83 | 114.13 | 1.95M |
| Oct 2, 2026 | 116.76 | 117.19 | 114.57 | 115.30 | 2.17M |
| Oct 1, 2026 | 120.47 | 121.22 | 117.00 | 117.14 | 2.36M |
| Sep 30, 2026 | 123.00 | 124.23 | 121.03 | 121.35 | 1.62M |
| Sep 29, 2026 | 123.67 | 125.47 | 121.89 | 123.20 | 1.72M |
| Sep 28, 2026 | 123.32 | 126.14 | 122.53 | 124.82 | 1.43M |
| Sep 25, 2026 | 125.72 | 126.00 | 123.07 | 123.89 | 1.21M |
| Sep 24, 2026 | 124.79 | 125.55 | 123.03 | 124.44 | 1.40M |
| Sep 23, 2026 | 127.51 | 128.21 | 123.89 | 124.64 | 1.53M |
| Sep 22, 2026 | 124.72 | 127.75 | 124.01 | 126.93 | 1.65M |
| Sep 21, 2026 | 125.00 | 127.41 | 124.19 | 124.65 | 1.27M |
About Incyte
Incyte (INCY) is listed on the Nasdaq and classified by the SEC under “Services-Commercial Physical & Biological Research”. Its business address is in WILMINGTON, DE. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 879169.
INCY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| L.P. 667, | Director | Jul 2, 2026 |
| Bros. Advisors Lp Baker | Director | Jul 2, 2026 |
| Felix Baker | Director | Jul 2, 2026 |
| Julian Baker | Director | Jul 2, 2026 |
| Jean Jacques Bienaime | Director | Jun 10, 2026 |
| Otis W Brawley | Director | Jun 10, 2026 |
| Bros. Advisors (Gp) Llc Baker | Director | Jul 2, 2026 |
| Brothers Life Sciences Lp Baker | Director | Jul 2, 2026 |
| Paul J Clancy | Director | Jul 2, 2026 |
| Jacqualyn A Fouse | Director | Jun 10, 2026 |
| Edmund Harrigan | Director | Jul 2, 2026 |
| Katherine A High | Director | Jun 10, 2026 |
| Herve Hoppenot | Director | Dec 10, 2025 |
| William Meury | Chief Executive Officer | Jul 20, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ramitpal K Basi | EVP, Human Resources | Aug 27, 2026 |
| Pablo J Cagnoni | President, Global Head of R&D | Sep 17, 2026 |
| Sheila A. Denton | EVP & General Counsel | Nov 19, 2025 |
| David H Gardner | EVP, Chief Strategy Officer | Sep 24, 2026 |
| Lee Heeson | EVP, Head of Incyte Intl | Jul 27, 2026 |
| Richard A. Hoffman | EVP & General Counsel | Jul 20, 2026 |
| Mohamed Khairie Issa | EVP, Head of U.S. Commercial | Jul 20, 2026 |
| Patrick A Mayes | EVP & Chief Scientific Officer | Aug 7, 2026 |
| William Meury | Chief Executive Officer | Jul 20, 2026 |
| Michael James Morrissey | EVP, Head of Tech. Operations | Jul 27, 2026 |
| Steven H Stein | CMO & Head of Late-Stage Dev. | Jul 20, 2026 |
| Thomas Tray | Principal Accounting Officer | Jul 20, 2026 |
| Matteo Trotta | EVP, GM, Dermatology US | Mar 26, 2026 |
| Suketu Upadhyay | EVP & Chief Financial Officer | May 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Pablo J Cagnoni | Sale | 9,233 | $120.50 |
| Sep 15, 2026 | Pablo J Cagnoni | Sale | 13,985 | $120.49 |
| Sep 15, 2026 | Pablo J Cagnoni | Sale | 9,233 | $120.50 |
| Sep 15, 2026 | Pablo J Cagnoni | Sale | 13,985 | $120.49 |
| Sep 15, 2026 | Pablo J Cagnoni | Sale | 9,233 | $120.50 |
| Sep 15, 2026 | Pablo J Cagnoni | Sale | 13,985 | $120.49 |
| Sep 15, 2026 | Pablo J Cagnoni | Sale | 9,233 | $120.50 |
| Sep 15, 2026 | Pablo J Cagnoni | Sale | 13,985 | $120.49 |
| Aug 19, 2026 | Pablo J Cagnoni | Sale | 10,801 | $125.56 |
| Aug 19, 2026 | Pablo J Cagnoni | Sale | 10,801 | $125.56 |
| Aug 19, 2026 | Pablo J Cagnoni | Sale | 10,801 | $125.56 |
| Aug 19, 2026 | Pablo J Cagnoni | Sale | 10,801 | $125.56 |
| Aug 12, 2026 | Pablo J Cagnoni | Sale | 10,803 | $120.04 |
| Aug 12, 2026 | Pablo J Cagnoni | Sale | 10,803 | $120.04 |
| Aug 12, 2026 | Pablo J Cagnoni | Sale | 10,803 | $120.04 |
INCY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $5.14B | $1.29B | 6.41 | $1.41B |
| Dec 31, 2024 | $4.24B | $32.62M | 0.15 | $335.34M |
| Dec 31, 2023 | $3.70B | $597.60M | 2.65 | $496.49M |
| Dec 31, 2022 | $3.39B | $340.66M | 1.52 | $969.94M |
| Dec 31, 2021 | $2.99B | $948.58M | 4.27 | $749.49M |
Latest balance sheet: total assets $7.34B, total liabilities $1.72B, cash $3.46B (as of Mar 31, 2026).
INCY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 28, 2026 | 8-K Item 2.02 (results) | $129.93 |
| Apr 28, 2026 | 8-K Item 2.02 (results) | $97.74 |
| Feb 10, 2026 | 8-K Item 2.02 (results) | $100.05 |
| Oct 28, 2025 | 8-K Item 2.02 (results) | $91.65 |
| Jul 29, 2025 | 8-K Item 2.02 (results) | $77.38 |
| Apr 29, 2025 | 8-K Item 2.02 (results) | $60.43 |
| Feb 10, 2025 | 8-K Item 2.02 (results) | $68.30 |
| Oct 29, 2024 | 8-K Item 2.02 (results) | $73.60 |
| Jul 30, 2024 | 8-K Item 2.02 (results) | — |
| Apr 30, 2024 | 8-K Item 2.02 (results) | — |
| Feb 13, 2024 | 8-K Item 2.02 (results) | — |
| Oct 31, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Services-Commercial Physical & Biological Research
Iqvia (IQV)Charles River Laboratories International (CRL)Icon (ICLR)Medpace (MEDP)Absci (ABSI)bioAffinity Technologies (BIAF)OmniAb (OABI)Nrc Health (NRC)Maxcyte (MXCT)iSpecimen (ISPC)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on INCY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.